1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
2
|
Wolpin BM and Mayer RJ: Systemic treatment
of colorectal cancer. Gastroenterology. 134:1296–1310. 2008.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Chung KY, Shia J, Kemeny NE, Shah M,
Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, et al:
Cetuximab shows activity in colorectal cancer patients with tumors
that do not express the epidermal growth factor receptor by
immunohistochemistry. J Clin Oncol. 20:1803–1810. 2005. View Article : Google Scholar
|
4
|
Bokemeyer C, Bondarenko I, Hartmann JT, de
Braud F, Schuch G, Zubel A, Celik I, Schlichting M and Koralewski
P: Efficacy according to biomarker status of cetuximab plus
FOLFOX-4 as first-line treatment for metastatic colorectal cancer:
the OPUS study. Ann Oncol. 22:1535–1546. 2011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417.
2009.PubMed/NCBI
|
6
|
Walther A, Johnstone E, Swanton C, Midgley
R, Tomlinson I and Kerr D: Genetic prognostic and predictive
markers in colorectal cancer. Nat Rev Cancer. 9:489–499. 2009.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Bardelli A and Siena SJ: Molecular
mechanisms of resistance to cetuximab and panitumumab in colorectal
cancer. Clin Oncol. 28:1254–1261. 2010. View Article : Google Scholar : PubMed/NCBI
|
8
|
Winder T and Lenz HJ: Vascular endothelial
growth factor and epidermal growth factor signaling pathways as
therapeutic targets for colorectal cancer. Gastroenterology.
138:2163–2176. 2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Chua W, Goldstein D, Lee CK, Dhillon H,
Michael M, Mitchell P, Clarke SJ and Iacopetta B: Molecular markers
of response and toxicity to FOLFOX chemotherapy in metastatic
colorectal cancer. Br J Cancer. 101:998–1004. 2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Gilje B, Heikkilä R, Oltedal S, Tjensvoll
K and Nordgard O: High-fidelity DNA polymerase enhances the
sensitivity of a peptide nucleic acid clamp PCR assay for K-ras
mutations. Mol Diagn. 10:325–331. 2008. View Article : Google Scholar : PubMed/NCBI
|
11
|
Forbes S, Clements J, Dawson E, Bamford S,
Webb T, Dogan A, Flanagan A, Teague J, Wooster R, Futreal PA and
Stratton MR: COSMIC 2005. Br J Cancer. 94:318–322. 2006. View Article : Google Scholar
|
12
|
Poehlmann A, Kuester D, Meyer F, Lippert
H, Roessner A and Schneider-Stock R: K-ras mutation detection in
colorectal cancer using the Pyrosequencing technique. Pathol Res
Pract. 203:489–497. 2007. View Article : Google Scholar : PubMed/NCBI
|
13
|
Raponi M, Winkler H and Dracopoli NC: KRAS
mutations predict response to EGFR inhibitors. Curr Opin Pharmacol.
8:413–418. 2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Saif MW and Shah M: K-ras mutations in
colorectal cancer: a practice changing discovery. Clin Adv Hematol
Oncol. 7:45–53. 2009.PubMed/NCBI
|
15
|
Klein CA: Parallel progression of primary
tumours and metastases. Nat Rev Cancer. 9:302–312. 2009. View Article : Google Scholar : PubMed/NCBI
|
16
|
Knijn N, Mekenkamp LJ, Klomp M,
Vink-Börger ME, Tol J, Teerenstra S, Meijer JW, Tebar M, Riemersma
S, van Krieken JH, et al: KRAS mutation analysis: a comparison
between primary tumours and matched liver metastases in 305
colorectal cancer patients. Br J Cancer. 104:1020–1026. 2011.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Vogelstein B, Fearon ER, Hamilton SR, Kern
SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos
JL: Genetic alterations during colorectal-tumor development. N Engl
J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
|
18
|
Wang JY, Yeh CS, Chen YF, Wu CH, Hsieh JS,
Huang TJ, Huang SY and Lin SR: Development and evaluation of a
colorimetric membrane-array method for the detection of circulating
tumor cells in the peripheral blood of Taiwanese patients with
colorectal cancer. Int J Mol Med. 17:737–747. 2006.
|
19
|
Lindforss U, Zetterquist H,
Papadogiannakis N and Olivecrona H: Persistence of K-ras mutations
in plasma after colorectal tumor resection. Anticancer Res.
25:657–661. 2005.PubMed/NCBI
|
20
|
Beau-Faller M, Legrain M, Voegeli AC,
Guérin E, Lavaux T, Ruppert AM, Neuville A, Massard G, Wihlm JM,
Quoix E, et al: Detection of K-ras mutations in tumor samples of
patients with non-small cell lung cancer using PNA-mediated PCR
clamping. Br J Cancer. 100:985–992. 2009. View Article : Google Scholar : PubMed/NCBI
|